Post-earnings recap
Reported
Wed, Jul 29, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a narrower-than-expected loss per share, which led to a slight increase in stock price by 0.30%. The company did not disclose revenue figures, leaving some uncertainty for investors. Management's cautious optimism suggests they are focused on their clinical programs, but the lack of guidance may leave investors wanting more clarity on future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.13 | N/A | +8.45% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding their operational progress. However, they did not provide detailed guidance for future performance.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing efforts in their clinical programs.